Konica Minolta has developed the SPFS Immunoassay System, which comprises a compact unit for highly sensitive measurement of troponin with a diagnosis time of just 3 hours, and a set of heart disease-related reagents, including troponin.

The SPFS Immunoassay System will be able to dramatically increase the efficiency of diagnostic and other clinical activities, and lessen overcrowding in emergency care settings, thus helping to reduce patient mortality rates and facilitate early recovery and discharge.

Furthermore, the SPFS Immunoassay System can accurately detect disease-specific biomarkers (proteins found specifically in target diseases) to provide highly reliable immunoassay system not only for heart diseases such as myocardial infarction, but also for malignancies (cancer) and other diseases, thus improving medical care.

Konica Minolta is planning to launch the SPFS Immunoassay System incorporating markers related to heart diseases primarily in Europe in 2017, and then sell it in both the European and American markets.

Konica Minolta is also planning to create a more efficient immunoassay system with a greater number of test parameters, and to fully enter the in vitro diagnostics market with the high-sensitivity immunoassay system.